There are provided a therapeutic preparation for anxiety neurosis or depression
which comprises a MC4 receptor antagonist as an effective ingredient;
and a piperazine derivative represented by Formula [1]:
##STR1##
[wherein Ar1 is a phenyl group, a substituted phenyl group, a
naphthyl group or a substituted naphthyl group; Ar2 is a naphthyl group,
a substituted naphthyl group, a quinolyl group, a group represented by the formula:
##STR2##
(wherein R4 is a hydrogen atom or a halogen atom; and X—Y
is CH—NH, CH—O, CH—S or N—O) or a group represented by
the formula:
##STR3##
(wherein R5 is a hydrogen atom, a hydroxyl group or a C1-10
alkoxy group); R1 is a hydrogen atom, a C1-10 alkyl group,
a C3-8 cycloalkyl group, a C3-10 alkenyl group, a phenyl
group, a 1-cyanoethyl group, a pyrimidin-2-yl group or an amidyl group; R2
and R3 are the same or different, and are each a hydrogen atom
or a C1-10 alkyl group; A-B is N—CH2, CH—CH2,
C(OH)—CH2 or CCH; T1 is a single bond, —N(R6)—
(wherein R6 is a hydrogen atom or a C1-10 alkyl group), —O—,
—CHCH— or —C(O)—; n is an integer of from
1 to 10 and when T1 is a single bond, —CHCH— or
—C(O)—, n is an integer of from 2 to 10 when T1 is
—N(R6)— or —O—], or a pharmaceutically acceptable
salt thereof.